Pharmacopeia

CWP-0270

VERAPAMIL

Cardiovascular · Level 3

Core pharmacology

Introduction

Phenylalkylamine
(Non-dihydropyridine calcium channel blocker)

Synthetic papaverine derivative

Indications Uses

HTN
Angina
Paroxysmal SVT and AFib/Aflutter

Mechanism of action

Binds to V binding site of L-type channel.
Levoisomer: main effects (arterial vasodilation). Slows conduction through the AV and SA node to a greater extent than other CCBs.
Dextro: Only acts on fast sodium channels, accounting for local anesthetic effects (1.6x potent as procaine)

Protein binding

~90%

Volume of distribution

3.89 L/kg

Metabolism

Hepatic via multiple CYP isoenzymes, one active metabolite with 20% activity

Excretion

Urine (70% metab, 3% to 4% unchanged); feces (16%)

Half-life

3-7 hours

Route And Dose

40mgPO or 5-10mg IV.

Chemical Pharmaceutics

Racemic mixture.

Onset Peak Duration

on/ dur 1-2 hrs / 6-8 hrs (PO)

Class Group

Non-dihydropyridine calcium-channel blocker; Vaughan Williams class IV antiarrhythmic.

Presentation

Available in oral immediate/modified-release formulations and as an IV preparation; exact strengths vary by product.

Absorption

Completely absorbed orally. Oral bioavailability 10-22% because of significant first-pass metabolism.

Physiological effects

CVS: slow conduction of AP at SA and AV node, negatively inotropic, peripheral vasodilation (↓SVR), arrhythmia (heart block, VF in WPW). CNS: ↑CBF, may potentiate effects of depol/NDMBs. GIT - Constipn/Nausea

Adverse Effects Toxicity

Dizziness, nausea, flushing, postural hypotension.
in patients without CCF: ↑LV fn by improving ischemia. In pts with CCF: ↓contractility and LV fn. Should be avoided in pts with WPW- cause VT/VF.
Inhibits CYP3A4.